OS Therapies Inc. (OSTX) is stepping into the spotlight in Q4 2025, propelled by a pivotal regulatory update that could redefine its path to market.
Company Overview
OS Therapies is a clinical-stage biopharmaceutical company headquartered in Grasonville, Maryland, focused on developing innovative treatments for osteosarcoma and other solid tumors. Founded in 2018, the company has built its pipeline around two core platforms: OST-HER2, an off-the-shelf immunotherapy targeting HER2-positive osteosarcoma, and OST-tADC, a tunable antibody-drug conjugate technology that uses pH-sensitive silicone dioxide linkers to deliver cytotoxic payloads with precision and reduced systemic toxicity.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.